2021
Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies
Katoch D, Krishnamurti L. Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies. Patient Preference And Adherence 2021, 15: 2221-2229. PMID: 34629865, PMCID: PMC8493010, DOI: 10.2147/ppa.s264918.Peer-Reviewed Original ResearchSickle cell diseasePatient preferencesTreatment preferencesCell diseasePediatric sickle cell diseaseHematopoietic cell transplantPatients' treatment preferencesBurden of careQuality of lifeQualitative studyStandard gamble studyCurative intentRed blood cellsSupportive careSubstantial morbidityCell transplantImpaired qualityTreatment optionsIntravascular hemolysisPatient utilitiesPremature mortalityCaregiver perspectivesTreatment alternativesBlood cellsUtility studies
2005
Mixed Hematopoietic Chimerism for Sickle Cell Disease Prevents Intravascular Hemolysis and Corrects Biomarkers of Endothelial Function.
Wu C, Krishnamurti L, Gladwin M, Biernacki M, Rogers S, Wang X, Zahrieh D, Antin J, Ritz J. Mixed Hematopoietic Chimerism for Sickle Cell Disease Prevents Intravascular Hemolysis and Corrects Biomarkers of Endothelial Function. Blood 2005, 106: 2333. DOI: 10.1182/blood.v106.11.2333.2333.Peer-Reviewed Original ResearchSickle cell diseaseMixed hematopoietic chimerismStem cell transplantationEndothelial functionIntravascular hemolysisMixed chimerismPulmonary hypertensionDonor engraftmentCell transplantationVascular functionHematopoietic chimerismNonmyeloablative allogeneic stem cell transplantationChronic end-organ damageAllogeneic stem cell transplantationEnd-organ injuryExperienced graft rejectionEnd-organ damageEnd-organ toxicityPre-transplant levelsDonor cell engraftmentChronic intravascular hemolysisSuccess of therapyFree Hb concentrationEndothelial dysfunctionGraft rejection